Moderate to Severe Plaque Psoriasis Market Outlook

Thelansis’s “Moderate to Severe Plaque Psoriasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Plaque Psoriasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate to Severe Plaque Psoriasis Overview

Moderate-to-severe plaque psoriasis is a chronic, immune-mediated disorder characterized by keratinocyte hyperproliferation and erythematous plaques with silvery scales. Driven by the IL-23/Th17 axis, genetic susceptibility (notably HLA-Cw6), and environmental triggers, it inflicts a heavy cardiometabolic and psychosocial burden. Because a third of patients develop psoriatic arthritis, routine joint screening is mandatory. While mild disease responds to topicals, moderate-to-severe presentations require advanced systemic intervention, which has completely evolved past standard step-up models. The biologic armamentarium has dramatically expanded beyond single-cytokine blockers with the approval of Bimzelx (bimekizumab), a first-in-class dual IL-17A and IL-17F inhibitor delivering unprecedented complete skin clearance (PASI 100) rates. Crucially, the oral treatment paradigm has been completely redefined. While the allosteric TYK2 inhibitor Sotyktu (deucravacitinib) remains an option, it faces pressure from the FDA approval of Icotyde (icotrokinra)—a groundbreaking, first-in-class targeted oral peptide that directly blocks the IL-23 receptor to deliver biologic-level efficacy in a daily pill. Paired with next-gen pipeline agents like Takeda’s potent TYK2 inhibitor zasocitinib, modern management achieves rapid, durable clearance while systematically minimizing long-term cardiovascular risks.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)